Research And Development
Health
Medical

OPKO Health

$2.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (1.98%) Today
+$0.01 (0.39%) After Hours

Why Robinhood?

You can buy or sell OPKO Health and other stocks, options, ETFs, and crypto commission-free!

About

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. Read More The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Employees
5,690
Headquarters
Miami, Florida
Founded
1991
Market Cap
1.48B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
5.75M
High Today
$2.57
Low Today
$2.50
Open Price
$2.54
Volume
1.20M
52 Week High
$6.40
52 Week Low
$2.34

Collections

Research And Development
Health
Medical
Healthcare
Pharmaceutical
Biotechnology
Technology
US

News

Seeking AlphaMar 21

OPKO up 7% premarket on positive OPK88003 data

OPKO Health (NASDAQ:OPK) is up 7% premarket on increased volume on the heels of positive topline results from a Phase 2 dose-escalation study evaluating OPK88003, a weekly injectable oxyntomodulin compound with dual glucagon-like-peptide 1 (GLP-1) and glucagon agonist activity, in adult type 2 diabetics with inadequate blood sugar control with metformin and/or diet and exercise.

76
Yahoo FinanceMar 21

OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

OPKO Health’s Oxyntomodulin, OPK88003, Shows Significant Reduction in HbA1c and Body Weight in Patients with Type 2 Diabetes MIAMI, March 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and obesity. OPK88003 is a once-weekly injectable oxyntomodulin compound with glucagon-like-peptide 1 (GLP-1) and glucagon dual agonist activity. Based on data from a previous 420 patient Phase 2 study, an...

141
Yahoo FinanceMar 4

OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues

OPKO Health, Inc. OPK incurred adjusted loss of 8 cents per share in fourth-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The company had incurred a loss of 12 cents per share in the year-ago quarter. On a GAAP basis, the Zacks Rank #3 (Hold) company incurred a loss of 13 cents per share. Revenues totaled $221.9 million, which missed the Zacks Consensus Estimate of $242 million. However, on a year-over-year basis, the top line increased 37.8%. 2018 at a Glance Net revenu...

211

Earnings

-$0.32
-$0.22
-$0.11
-$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.